Jasper Therapeutics, Inc. (JSPRW)
NCM
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.
Peers in industry
Jasper Therapeutics, Inc. has no peer companies in this window.
Recent press releases
Jasper Therapeutics, Inc. has not issued a press release in this window.
SEC filings
All filings →Jasper Therapeutics, Inc. has not filed an SEC document in this window.
Insider trades
All insider trades →Jasper Therapeutics, Inc. has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at Jasper Therapeutics, Inc.
All people →No officers or directors have been indexed for Jasper Therapeutics, Inc..